NYSE:SNDR
NYSE:SNDRTransportation

Schneider National (SNDR): Evaluating Valuation After Mixed Q3 Results With Rising Sales and Falling Profits

Schneider National just released its third quarter results. The report shows higher sales year-over-year, but net income and earnings per share are both lower than last year. Investors took note of the revenue growth along with lower profitability. See our latest analysis for Schneider National. After announcing increased sales but lower profits for the quarter, Schneider National’s share price saw a small bounce, rising 2.66% in a day and 6.46% over the last week. Still, bigger picture...
NYSE:KNX
NYSE:KNXTransportation

Knight-Swift (KNX): Assessing Valuation After Recent Share Price Rebound

Knight-Swift Transportation Holdings (KNX) shares have seen some movement lately, and investors are watching closely to see how the company’s recent performance lines up with the broader transportation sector. The stock’s year-to-date return remains in focus. See our latest analysis for Knight-Swift Transportation Holdings. After a tough start to the year, Knight-Swift’s 1-day share price return of 4.47% stands out as an encouraging sign. Year-to-date share price return remains down at...
NasdaqGS:BOKF
NasdaqGS:BOKFBanks

Is BOK Financial's (BOKF) $400 Million Capital Raise Shifting Its Long-Term Risk and Earnings Profile?

BOK Financial Corporation recently announced a US$0.6300 per share quarterly dividend, payable on November 26, 2025, with an ex-date and record date of November 12, 2025. In addition, BOKF, NA has completed a US$400 million subordinated notes offering to boost its Tier II regulatory capital and fund general corporate purposes. We'll examine how BOK Financial’s US$400 million capital raise could influence its risk profile and longer-term earnings outlook. We've found 16 US stocks that are...
NasdaqGS:DNLI
NasdaqGS:DNLIBiotechs

Why Denali Therapeutics (DNLI) Is Down 7.7% After Widening Losses and Key Leadership Changes

Denali Therapeutics recently reported third quarter and nine-month 2025 results, with net losses widening to US$126.9 million and US$383.99 million respectively, while also announcing the departure of its long-standing Chief Medical Officer, Carole Ho, M.D., who will join Eli Lilly, and naming a new board member, Tim Van Hauwermeiren. This combination of financial performance and leadership transition marks a pivotal period for Denali, underscoring both operational challenges and evolving...